Dabigatran: A new oral anticoagulant
Dabigatran, a direct thrombin inhibitor (DTI), has been approved as a new orally administrated anticoagulant in many countries including Thailand. Food and drug administration (FDA) Thailand has approved 75, 110 and 150 mg of dabigatran since 2009 for prevention of stroke and venous thromboembolism...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
2015
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/1103 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Language: | English |
id |
th-mahidol.1103 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.11032023-04-12T15:27:06Z Dabigatran: A new oral anticoagulant Sirada Srihirun สิรดา ศรีหิรัญ Nathawut Sibmooh ณัฐวุธ สิบหมู่ Sirada Srihirun สิรดา ศรีหิรัญ Mahidol University. Faculty of Dentistry. Department of Pharmacology Mahidol University. Faculty of Science. Department of Pharmacology Pradaxa Dabigatran Direct thrombin inhibitor Novel oral anticoagulant Bleeding Oral surgery Open Access article วิทยาสารทันตแพทยศาสตร์มหิดล Mahidol Dental Journal Dabigatran, a direct thrombin inhibitor (DTI), has been approved as a new orally administrated anticoagulant in many countries including Thailand. Food and drug administration (FDA) Thailand has approved 75, 110 and 150 mg of dabigatran since 2009 for prevention of stroke and venous thromboembolism (VTE) in atrial fibrillation (AF), orthopedic surgery as well as treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Dentists may encounter patients who receive dabigatran therapy. Although tooth extractions are minor surgery done at outpatient unit, patients with high risk of hemorrhage must be carefully assessed with proper dental management. This article describes pharmacological properties of dabigatran including discovery, pharmacokinetics, pharmacodynamics, clinical trials, and adverse effects. In addition, the suggestion for dental management of patients being treated with dabigatran has been stated. 2015-06-27T03:33:48Z 2017-01-05T06:57:16Z 2015-06-27T03:33:48Z 2017-01-05T06:57:16Z 2015-06-16 2015-01 Article Srihirum S, sibmooh N. Dabigatrain : A new oral anticoagulant. M Dent J. 2015; 35(1): 79-89. 0125-5614 (printed) https://repository.li.mahidol.ac.th/handle/123456789/1103 eng Mahidol University Faculty of Dentistry Mahidol University application/pdf |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
language |
English |
topic |
Pradaxa Dabigatran Direct thrombin inhibitor Novel oral anticoagulant Bleeding Oral surgery Open Access article วิทยาสารทันตแพทยศาสตร์มหิดล Mahidol Dental Journal |
spellingShingle |
Pradaxa Dabigatran Direct thrombin inhibitor Novel oral anticoagulant Bleeding Oral surgery Open Access article วิทยาสารทันตแพทยศาสตร์มหิดล Mahidol Dental Journal Sirada Srihirun สิรดา ศรีหิรัญ Nathawut Sibmooh ณัฐวุธ สิบหมู่ Dabigatran: A new oral anticoagulant |
description |
Dabigatran, a direct thrombin inhibitor (DTI), has been approved as a new orally administrated anticoagulant in many countries including Thailand. Food and drug administration (FDA) Thailand has approved 75, 110 and 150 mg of dabigatran since 2009 for prevention of stroke and venous thromboembolism (VTE) in atrial fibrillation (AF), orthopedic surgery as well as treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Dentists may encounter patients who receive dabigatran therapy. Although tooth extractions are minor surgery done at outpatient unit, patients with high risk of hemorrhage must be carefully assessed with proper dental management. This article describes pharmacological properties of dabigatran including discovery, pharmacokinetics, pharmacodynamics, clinical trials, and adverse effects. In addition, the suggestion for dental management of patients being treated with dabigatran has been stated. |
author2 |
Sirada Srihirun |
author_facet |
Sirada Srihirun Sirada Srihirun สิรดา ศรีหิรัญ Nathawut Sibmooh ณัฐวุธ สิบหมู่ |
format |
Article |
author |
Sirada Srihirun สิรดา ศรีหิรัญ Nathawut Sibmooh ณัฐวุธ สิบหมู่ |
author_sort |
Sirada Srihirun |
title |
Dabigatran: A new oral anticoagulant |
title_short |
Dabigatran: A new oral anticoagulant |
title_full |
Dabigatran: A new oral anticoagulant |
title_fullStr |
Dabigatran: A new oral anticoagulant |
title_full_unstemmed |
Dabigatran: A new oral anticoagulant |
title_sort |
dabigatran: a new oral anticoagulant |
publishDate |
2015 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/1103 |
_version_ |
1781415224396480512 |